Evans Ronald M, Barish Grant D, Wang Yong-Xu
Gene Expression Laboratory, Howard Hughes Medical Institute, The Salk Institute for Biological Studies, La Jolla, California 92037, USA.
Nat Med. 2004 Apr;10(4):355-61. doi: 10.1038/nm1025.
Obesity and the related disorders of dyslipidemia and diabetes (components of syndrome X) have become global health epidemics. Over the past decade, the elucidation of key regulators of energy balance and insulin signaling have revolutionized our understanding of fat and sugar metabolism and their intimate link. The three 'lipid-sensing' peroxisome proliferator-activated receptors (PPAR-alpha, PPAR-gamma and PPAR-delta) exemplify this connection, regulating diverse aspects of lipid and glucose homeostasis, and serving as bona fide therapeutic targets. With molecular underpinnings now in place, new pharmacologic approaches to metabolic disease and new questions are emerging.
肥胖以及与之相关的血脂异常和糖尿病（X综合征的组成部分）已成为全球性的健康流行病。在过去十年中，对能量平衡和胰岛素信号关键调节因子的阐明彻底改变了我们对脂肪和糖代谢及其紧密联系的理解。三种“脂质感应”过氧化物酶体增殖物激活受体（PPAR-α、PPAR-γ和PPAR-δ）就是这种联系的例证，它们调节脂质和葡萄糖体内平衡的各个方面，并成为真正的治疗靶点。随着分子基础的确定，针对代谢疾病的新药物方法和新问题不断涌现。
